Generation Bio is looking to move the field of gene therapy into the future, and thinks it has a manufacturing process in place that will allow enough scale for broad disease indications. Now, all it needs is a plant to put those large-scale ambitions into action.
Now 10 years into the golden era of immuno-oncology (I-O) following the first FDA approval of ipilimumab (anti-CTLA4) in 2011 and the seminal initial efficacy disclosure on nivolumab (anti-PD1) in 2012 (Topalian et al NEJM), we can reflect on how I-O has literally changed the lives of tens of thousands of cancer patients and their families.
By Tim Reilly & Jonathan Montagu, CDO and CEO of HotSpot Therapeutics, as part of the From The Trenches feature of LifeSciVC
Atlas Venture, a leading early stage venture capital firm, announced today that Jodie Morrison is joining the firm as a venture partner. Jodie will work with the Atlas team to build transformative new biotech companies.
Holy cow, have we seen the rain lately – both downpours outside and a downpour of SPAC activity.
By Sam Truex, Venture Partner at Atlas Venture, as part of the From The Trenches feature of LifeSciVC.
When I play board games, I play to win. That requires thinking several moves ahead. In the game Risk, for instance, it’s not enough to just conquer Australia. If you want to use the continent as a launch pad to take over the world, you need to design and execute on a long-term strategy.
By Joshua Brumm, CEO of Dyne Therapeutics, as part of the From The Trenches feature of LifeSciVC